GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (NSE:PPLPHARMA) » Definitions » NonCurrent Deferred Liabilities

Piramal Pharma (NSE:PPLPHARMA) NonCurrent Deferred Liabilities : ₹0 Mil (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Piramal Pharma NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Piramal Pharma's non-current deferred liabilities for the quarter that ended in Mar. 2024 was ₹0 Mil.

Piramal Pharma NonCurrent Deferred Liabilities Historical Data

The historical data trend for Piramal Pharma's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Piramal Pharma NonCurrent Deferred Liabilities Chart

Piramal Pharma Annual Data
Trend Mar21 Mar22 Mar23 Mar24
NonCurrent Deferred Liabilities
- - - -

Piramal Pharma Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Piramal Pharma NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Piramal Pharma's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Piramal Pharma (NSE:PPLPHARMA) Business Description

Traded in Other Exchanges
Address
Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, MH, IND, 400070
Piramal Pharma Ltd offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. It includes integrated contract development and manufacturing organization business, complex hospital generics business, and India consumer healthcare business, selling over-the-counter products in India.

Piramal Pharma (NSE:PPLPHARMA) Headlines

No Headlines